dcsimg

Innovative Drug Development

Bayer offers financial support to evaluate your antibody or derivate and to promote its exploration for a potential new drug development.

Submissions open until
June 30th 2017

partneryourantibodies

Our Focus

Bayer‘s R&D focusses on identifying and developing novel drugs (including antibodies and antibody derivatives) for treating diseases with high unmet medical need. We are committed to innovation and to translating initial ideas from basic research into novel drugs. Complementing our internal efforts, we are dedicated to fostering collaborations with academic groups, start-up and biotech companies.

This is What We Are Aiming For

1
Antibody discovery
2
Discovery of biological activity
3
Characterization
4
Final candidate
1
Antibody discovery
2
Discovery of biological activity
3
Characterization
4
Final candidate

With our PartnerYourAntibodies® initiative we are looking for novel antibodies relating particularly to the fields of cardiovascular (covering heart, vascular, hemostatic and acute organ disorders, specialty lung and kidney diseases), oncology as well as gynecology and addressing a specific target or pathway in a selective manner (functional activity). Successful applications will be assessed by us with regard to bioactivity.

If confirmed, we might initiate a joint antibody-exploration project with you, in which case you would receive substantial financial funding from Bayer to compensate for your research expenses. Such a collaboration would then be subject to the negotiation of a contract reflecting the interests of all parties involved.

Our indication areas of interest

  • Cardiovascular (covering heart, vascular, hemostatic and acute organ disorders, specialty lung and kidney diseases)
  • Oncology
  • Gynecology

A Long History With Bayer

Bayer today: Bayer’s research center in Wuppertal Bayer today: Bayer’s research center in Wuppertal

A Long History With Bayer

Bayer is an experienced partner with a long tradition of successful and reliable global partnerships. The company offers access to advanced drug-discovery know-how and technologies. Bayer is active in the field of biologics, especially protein therapeutics in the search for new drugs. If your antibody is selected for collaboration, you may in some cases – subject to entering into a collaboration with Bayer – be given an opportunity to use innovative technologies, complementary expertise and resources.

How It Works

1
Application
Deadline: June 30th 2017
2
Review
Approx. 8-week process
3
Decision
Announced: Sept. 2017
4
Collaboration
From Oct. 2017
1
Application
Deadline: June 30th 2017
2
Review
Approx. 8-week process
3
Decision
Announced: Sept. 2017
4
Collaboration
From Oct. 2017

The submission is non-confidential and should include information on the antibody properties, including such biological data as
- Species (e.g. human, murine,…)*
- Origin (e.g. phage display, immunization,…)*
- Used Library (for phage display derived antibodies) or host*
- Clonality (mono- or polyclonal)*
- Amount available (mg) and Concentration (mg/ml)*
- Cross-Reactivity (e.g. human, murine, rat, non-human primate,…)
- Target, Pathway or Specificity (NO details on epitope)*
- Assay used to test biological activity*
- Affinity to target or ED50 in FACS analysis

Please use the submission tool to submit your data, filling all mandatory (*) information. Submitting optional information might accelerate review of your application.

For intellectual property (IP) reasons, please do NOT reveal the amino acid sequence, even if the sequence has already been published. Further, please do NOT provide the binding epitope.
After submitting your proposal, you will receive a confirmation email containing a registration number, for use in all further communication.

The submission is open until June 30th 2017.

Your submission will be reviewed by senior scientists at Bayer . The outcome of our assessment is entirely at our discretion without any obligation to justify it or to give reasons. In evaluating your decision, we will consider the following:

1. Antibody descriptors

Read More

At the non-confidential level we will determine our interest in your asset based on molecular descriptors without sequence information. Descriptors – such as species, origin, used library or host, clonality, amount available and concentration, cross-reactivity, target etc. – help us gauge the antibody’s suitability or liability in terms of drug-like properties.
When reviewing your submission we do not use drug-like properties as strict cut-off criteria, but see them as risk alerts that must be taken into account in future optimization strategy.

2. Biological activity

Read More

The target addressed by the antibody and the antibodies potency against this target is a very important piece of information. Our primary interest lies with antibodies addressing targets or pathways in the fields of oncology, cardiology (including kidney diseases), hemophilia and gynecological therapies.

If our assessment of your submission is positive, we want to find out more about your antibody or derivative and will contact you to determine the next steps. We might already provide you a reasonable monetary compensation for your effort at this stage.

Option 1: Bayer evaluates compounds in assays under a Material Transfer Agreement (MTA)

Read More

Bayer evaluates antibodies in assays under a Material Transfer Agreement (MTA)
We are interested in assessing your antibody using our own assays and models and propose a MTA.

The MTA stipulates that material:

  • shall be provided by you to Bayer solely to enable Bayer to evaluate its interest in entering into a cooperation agreement;
  • shall be used by Bayer solely for investigational purposes;
  • shall be held in strict confidence and under restricted access;
  • shall be returned to you at your request.

 

At this point we have still not asked you to reveal the sequence or identity of your antibody.

Option 2: Bayer evaluates biological data on compounds under a Confidential Disclosure Agreement (CDA)

Read More

Bayer evaluates biological data on antibodies under a Confidential Disclosure Agreement (CDA). We might not have appropriate in-house assays to evaluate your antibody or derivative but would like to see more of your data on its biological activity. We therefore propose a CDA excluding the antibody sequence and identity to continue our discussion.

Briefly, the CDA stipulates that your information:

  • shall be disclosed to us solely to enable Bayer to evaluate its interest in entering into a cooperation agreement;
  • shall be kept strictly confidential by Bayer;
  • shall be returned to you at your request.

If we are convinced by the data generated under the MTA or assessed under a CDA, we would be interested in partnering with you to leverage the potential of the antibody by means of broader in vitro and in vivo characterization. At this point in time, we will propose a process by which you would reveal the amino acid sequence to us.

Depending on the antibody properties, we might propose a collaboration under an antibody exploration program, in which case you would receive substantial financial support from Bayer to compensate for your research expenses. This would entail negotiating a collaborative agreement reflecting the interests of all parties involved.

The submission is non-confidential and should include information and biological data on the antibody and its properties.

The submission is open until the June 30th 2017.

Please visit the PartnerYourAntibodies website on your desktop computer, laptop or tablet device to learn more about relevant information that you have to provide with your submission.

Your submission will be reviewed by senior scientists at Bayer in regards to predefined major criteria for our decision. Nevertheless, the decision is entirely at our discretion without any obligation to justify it or to give reasons.

Please visit the PartnerYourAntibodies website on your desktop computer, laptop or tablet device to learn more about the criteria for our decision.

If our assessment of your submission is positive, we want to find out more about your antibody or derivative and will contact you to determine the next steps. We might already provide you a reasonable monetary compensation for your effort at this stage.

Please visit the PartnerYourAntibodies website on your desktop computer, laptop or tablet device to learn more on our assessment options.

If we are convinced by the data generated under the MTA or assessed under a CDA, we would be interested in a collaboration with you to leverage the potential of the antibody by means of broader in vitro and in vivo characterization.

Please visit the PartnerYourAntibodies website on your desktop computer, laptop or tablet device to learn more on our possible collaboration.

Frequently Asked Questions

What is antibody-exploration?
Antibody-exploration is the process that corroborates the antibody’s suitability by assessing its physico-chemical properties and pharmacological activities both in vitro and in vivo.

Can I submit antibody derivatives?
Beside antibodies, submission of derivatives such as Fab, scFv, minibody or similar is possible.

Who is eligible to apply?
Researchers from universities, other academic research institutes, or start-up and biotech companies from all over the world are invited to apply.

Will the information provided be considered confidential?
No, the information provided will not be considered confidential. We will use the information provided in the submission form for an initial evaluation. Before asking for confidential data we will agree a Confidential Disclosure Agreement (CDA) with you.

Who will review the proposals?
The proposals will be reviewed by experienced scientists at Bayer .

Can I submit a proposal on behalf of a group?
Yes, you can submit a proposal on behalf of a group. However, please name your collaborators/coworkers in the respective field. When concluding a Material Transfer Agreement (MTA) or a Confidential Disclosure Agreement (CDA) you should be aware of the ownership of your antibody; signatures of representatives of your institution/organization might be needed during the assessment period.

Can I submit polyclonal antibodies as well?
We are primarily interested in monoclonal antibodies.

 

Do you have further questions? Get in touch!

*

Mandatory fields, please complete.
Please note that the information you send is non-confidential.
You will receive a confirmation email after your inquiry.

Thank you for your inquiry!
We will contact you shortly.

OK

Submission

About Your Antibody
Personal Details
Legal Notice
Topic
Antibody Description
Indication Area*
Biological Activity
Publication
Is, to your knowledge, the sequence or identity of your antibody already published?

Do you want to submit supporting information?
(e.g. presentations, manuscripts, ...)
* Mandatory fields
Personal Details
 
* Mandatory fields

I am aware that the information I am providing will be regarded as – and deemed to be non-confidential, and that no company of the Bayer Group shall have any obligation of any kind with respect to such information.

I consent to the storage and processing of my personal data as provided in this application by Bayer Pharma AG and any company of the Bayer Group for the purpose of evaluating this application.

I declare that I together with collaborators/coworkers (named in the submission form) generated the antibody and the data described. I am not knowingly violating the rights of any third party.

I declare that I do not submit any information on the amino acid sequence or on the binding epitope.

Please remember

The decision as to whether we enter into a collaboration will be made at the sole discretion of Bayer. Please note, that information you submit is non-confidential.

Thanks for your submission!

You’ve just submitted to PartnerYourAntibodies®! An email confirmation will be sent out to you shortly confirming that your application was successfully submitted.

OK

Warning!

An ERROR occurred during the submission of your proposal. Please send an e-mail (with the title of your submission) directly to partneryourantibodies@bayer.com. We will contact you shortly. Sorry for the inconvenience this may cause.

    OK

    This site is validated through an Extended Validation SSL certificate (EV-SSL).
    Current browsers indicate an EV-SSL certificate with a bright green address bar.
    Please ensure that Bayer AG is named as the certificate owner.

    Submit Now

    To provide the best experience for your PartnerYourAntibodies® application, the submission form is not available on mobile devices. Please use your desktop computer, laptop or tablet device.

    Submit Now

    More Open Innovation By Bayer

    Open Innovation Portal

    Bring your ideas and projects together with people who can make it happen and share our passion for new paths in life sciences.

    Visit site

    Grants4Indications

    Do you have an idea for a new indication using Bayer compounds?
    Bayer is promoting the exploration of new indications by offering grants and further financial support.

    Visit site

    CoLaborator

    Bayer offers a unique incubator for startup life-science companies whose drug targets and technologies align with Bayer’s interests.

    Visit site

    Contact us

    PartnerYourAntibodiesTM - Bayer Pharma AG
    Germany, 13342 Berlin

    partneryourantibodies@bayer.com

    Thanks for your message!

    We will contact you shortly.

    ×